ANI Pharma Inc Business Finance Contracts & Agreements
72 Contracts & Agreements
- Assignment Agreements (1 contract)
- Exchange Agreements (17)
- Indenture Agreements (5)
- Investment Agreements (1)
- Investor Rights Agreements (1)
- Loan Agreements (2)
- Note Agreements (1)
- Purchase Agreements (12)
- Registration Rights Agreements (1)
- Stock Agreements (12)
- Subscription Agreements (2)
- Underwriting Agreements (5)
- Warrant Agreements (12)
- Indenture, dated as of August 13, 2024, between ANI Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee (Filed With SEC on August 13, 2024)
- Amended 2022 Stock Plan, Form of Restricted Stock Grant Agreement (Employees) (Filed With SEC on May 23, 2024)
- Amended 2022 Stock Plan, Form of Restricted Stock Grant Agreement (Directors) (Filed With SEC on May 23, 2024)
- Assignment and (Filed With SEC on May 10, 2024)
- Amendment to Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc (Filed With SEC on February 29, 2024)
- Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc (Filed With SEC on February 29, 2024)
- Agreement of Purchase and Sale between ANI Pharmaceuticals Canada, Inc. and 1540700 Ontario Limited (Filed With SEC on February 23, 2024)
- Underwriting Agreement, dated May 11, 2023, by and between ANI Pharmaceuticals, Inc. and Guggenheim Securities, LLC (Filed With SEC on May 12, 2023)
- Asset Purchase Agreement between Holmdel Pharmaceuticals, LP and ANI Pharmaceuticals, Inc (Filed With SEC on May 10, 2022)
- Asset Purchase Agreement between Cranford Pharmaceuticals, LLC and ANI Pharmaceuticals, Inc (Filed With SEC on May 10, 2022)
- Underwriting Agreement, dated November 3, 2021, between ANI Pharmaceuticals, Inc. and Guggenheim Securities, LLC (Filed With SEC on November 4, 2021)
- Equity Commitment and Investment Agreement dated March 8, 2021 by and between ANI Pharmaceuticals, Inc. and Ampersand 2020 Limited Partnership (Filed With SEC on March 9, 2021)
- Inducement Stock Option Award Agreement, effective as of September 8, 2020, between ANI Pharmaceuticals, Inc. and Nikhil Lalwani (Filed With SEC on November 5, 2020)
- Form of Non- Statutory Stock Option Agreement (Filed With SEC on February 27, 2020)
- Form of Restricted Stock Grant Agreement (Filed With SEC on February 27, 2020)
- Asset Purchase Agreement between Amerigen Pharmaceuticals LTD. and ANI Pharmaceuticals, Inc (Filed With SEC on February 27, 2020)
- Amendment No. 4 to Asset Purchase Agreement between ANI Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc (Filed With SEC on May 9, 2019)
- Stock Purchase Agreement by and among WellSpring Pharma Services Inc., WSP Pharma Holdings, LLC, ANI Pharmaceuticals Canada Inc., and ANI Pharmaceuticals, Inc (Filed With SEC on November 6, 2018)
- Asset Purchase Agreement between AstraZeneca AB, AstraZeneca UK Limited, and ANI Pharmaceuticals, Inc (Filed With SEC on February 27, 2018)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 4, 2017)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 4, 2017)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 5, 2016)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on May 5, 2016)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for ConfidentialTreatment under Rule 406 under the Securities... (Filed With SEC on November 3, 2015)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under theSecurities... (Filed With SEC on November 3, 2015)
- [Signature Page to Additional Warrant Confirmation] (Filed With SEC on December 10, 2014)
- ANI PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 10, 2014 3.00% Convertible Senior Notes due 2019 (Filed With SEC on December 10, 2014)
- INDENTURE ANI PHARMACEUTICALS, INC. and THE BANK OF NEW YORK MELLON as Trustee (Filed With SEC on December 10, 2014)
- 3.00% Convertible Senior Notes due 2019 ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT December 4, 2014 (Filed With SEC on December 8, 2014)
- Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities... (Filed With SEC on November 10, 2014)
- FORM OF NON-STATUTORY STOCK OPTION AGREEMENT (Non-Employee Director) (Filed With SEC on April 4, 2014)
- 1,402,525 Shares ANI PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 5, 2014)
- FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (Filed With SEC on April 26, 2013)
- NOTE PURCHASE AGREEMENT (Filed With SEC on December 11, 2012)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
- Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the... (Filed With SEC on December 11, 2012)
